![]() ![]() Any forward-looking statements that are made in this press release speak only as of the date of this press release. Various factors may cause differences between Kite's expectations and actual results as discussed in greater detail in Kite's filings with the Securities and Exchange Commission, including without limitation in its Form 10-Q for the quarter ended June 30, 2016. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to advance the product pipeline, commercially launch KTE-C19 and research and develop additional product candidates. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit Sign up to follow on Twitter at Cautionary Note on Forward-Looking Statements is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACTâ„¢) designed to restore the immune system's ability to recognize and eradicate tumors. Food and Drug Administration and Priority Medicines (PRIME) regulatory support for DLBCL in the EU. ![]() KTE-C19 has been granted Breakthrough Therapy Designation status for diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), and primary mediastinal B-cell lymphoma (PMBCL) by the U.S. Kite Pharma's lead product candidate, KTE-C19, is an investigational therapy in which a patient's T cells are engineered to express a CAR to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias, and redirect the T cells to kill cancer cells. The live audio webcast can be accessed through the Events and Presentations section under the Investors tab of Kite's website at Following the live audio webcast, a replay will be available on Kite's website for approximately 30 days. The event and live webcast will begin at 12:00pm Eastern Time. (Nasdaq:KITE) today announced that it will hold an Investor Day on Octoin New York where the company will share updates on its advancing pipeline of chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates, next generation research and development programs, and KTE-C19 launch readiness. SANTA MONICA, Calif.-(BUSINESS WIRE)- Kite Pharma, Inc. Kite Pharma to Host Investor Day on OctoSpotlighting an Industry-Leading CAR/TCR Pipeline, Next Generation Research and Development, and KTE-C19 Launch Readiness ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |